Policy | February 01, 2026
Budget 2026 -27: Pharma sector cheers Rs. 10,000 crore Biopharma plan
The Union Budget makes a clear and timely choice by placing biopharma at the centre of India’s next manufacturing wave
The Union Budget makes a clear and timely choice by placing biopharma at the centre of India’s next manufacturing wave
The Union Budget 2026–27 accords strong priority to the upgradation and expansion of healthcare infrastructure and medical education
CSPC will receive an upfront $1.2 billion from AstraZeneca for access to eight programmes, AI molecular design capabilities, and the LiquidGel platform
UK Prime Minister Keir Starmer praised the initiative, saying: “Unlocking opportunities for British businesses across the globe and delivering for working people back home is always the driving force behind my international engagements."
LOTTE Biologics will provide advanced manufacturing services for monoclonal antibody intermediates and their conjugates
GCCL aims to leverage the partnership to expand strategic relationships with global CROs
The deal to acquire AT-01 (124-Iodine-evuzamitide) and AT-05 (PAR-Peptide + technetium-99m) underscores Bayer’s commitment to expanding in molecular imaging and advancing precision cardiology
The proceeds from the ?IP will be primarily utilized to meet the cash consideration payable to Mylan Inc. (Viatris) for buying out its shareholding in Biocon Biologics Limited
BioNTech is positioning 2026 as a defining year in its transition toward a multi-product oncology company
Subscribe To Our Newsletter & Stay Updated
